Adefovir Depivoxil for Decompensated Liver Cirrhosis Patients with Lamivudine-resistant Hepatitis B:

[Guest guest]

AASLD 2007

1000. Adefovir Depivoxil for Decompensated Liver Cirrhosis Patients with

Lamivudine-resistant Hepatitis B: Multi-center Long-term Results

H. Woo; J. Choi; S. Yoon; D. Suh; S. Paik; K. Han; S. Um; B. Kim; H. Lee; M.

Cho; C. Lee; D. Kim ; J. Hwang

Background/Aim

The effect and safety of adefovir dipivoxil for patients with decompensated

cirrhosis were not well known. Long-term efficacy and safety of adefovir

dipivoxil in decompensated cirrhosis patients with lamivudine-resistant

hepatitis B (HBV) were studied.

Methods

One hundred nineteen cirrhotic patients who developed hepatic decompensation

(any cirrhosis complication or Child-Pugh (CP) score ¡Ý 7) after lamivudine

treatment were enrolled from eleven university hospitals and treated with 10 mg

of adefovir dipivoxil for a median 33 months between January 2003 and October

2006. Lamivudine was switched to adefovir dipivoxil with or without overlap

period (median 2 months). We evaluated the overall survival rate and the

improvement of Child-Pugh score, virologic response (HBV DNA 25) by multivariate

analysis (p=0.020, HR1.270 95% C.I. [1.038-1.553]). 3) The mean change from

baseline CP score was -2.9±2.1 points (p

_________________________________________________________________

Climb to the top of the charts!  Play Star Shuffle:  the word scramble challenge

with star power.

http://club.live.com/star_shuffle.aspx?icid=starshuffle_wlmailtextlink_oct